Physician profile
Harnath Singh
NPI 1538133236
$1,460.87
in general payments reported to CMS, 2019-2025
23 companies · $89.40 in 2025
The $89.40 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $108 · 2021: $179 · 2022: $180 · 2023: $462 · 2024: $220 · 2025: $89.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731 · Education: $40.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.23 |
| Education | $40.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $210.95 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $190.97 | 2019-2024 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $141.44 | 2019-2024 | Jynarque |
| Horizon Therapeutics Plc | $133.49 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $106.48 | 2019-2025 | Vafseo |
| Opko Pharmaceuticals, LLC | $92.19 | 2020-2023 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $80.51 | 2023-2024 | Acthar |
| Glaxosmithkline, LLC. | $70.13 | 2021-2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $66.79 | 2021-2023 | |
| Amgen INC. | $64.89 | 2023-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $38.37 | 2023-2024 | Lupkynis |
| Daiichi Sankyo INC. | $37.25 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $30.42 | 2021 | |
| Nxstage Medical, INC. | $26.37 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.45 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $21.48 | 2019 | |
| Ardelyx, INC. | $21.17 | 2024 | Ibsrela |
| Genzyme Corporation | $20.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.31 | 2024 | |
| Shield Therapeutics INC | $17.64 | 2023 | Accrufer |
| Travere Therapeutics, INC. | $16.89 | 2024 | |
| Ani Pharmaceuticals, INC. | $15.98 | 2023 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $15.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harnath Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.